Your browser doesn't support javascript.
loading
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System.
Lamarca, Angela; Santos-Laso, Alvaro; Utpatel, Kirsten; La Casta, Adelaida; Stock, Simone; Forner, Alejandro; Adeva, Jorge; Folseraas, Trine; Fabris, Luca; Macias, Rocio I R; Krawczyk, Marcin; Krawczyk, Marek; Cardinale, Vincenzo; Braconi, Chiara; Alvaro, Domenico; Evert, Matthias; Banales, Jesus M; Valle, Juan W.
Afiliação
  • Lamarca A; Medical Oncology/Institute of Cancer Sciences, The Christie NHS Foundation Trust/University of Manchester, Manchester, United Kingdom.
  • Santos-Laso A; Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
  • Utpatel K; Institute of Pathology, University of Regensburg, Regensburg, Germany.
  • La Casta A; Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
  • Stock S; Institute of Pathology, University of Regensburg, Regensburg, Germany.
  • Forner A; BCLC group, Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain.
  • Adeva J; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), The National Institute of Health Carlos III, Madrid, Spain.
  • Folseraas T; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Fabris L; 7Section of Gastroenterology and the Norwegian PSC Research Center, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
  • Macias RIR; Department of Molecular Medicine, University of Padua, Padua, Italy.
  • Krawczyk M; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), The National Institute of Health Carlos III, Madrid, Spain.
  • Krawczyk M; Experimental Hepatology and Drug Targeting (HEVEPHARM) group, University of Salamanca, IBSAL, Salamanca, Spain.
  • Cardinale V; Department of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany.
  • Braconi C; Laboratory of Metabolic Liver Diseases, Centre for Preclinical Research, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
  • Alvaro D; Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
  • Evert M; Gastroenterology, Sapienza University of Rome, Rome, Italy.
  • Banales JM; Medical Oncology, The University of Glasgow, Glasgow, United Kingdom.
  • Valle JW; Gastroenterology, Sapienza University of Rome, Rome, Italy.
Hepatology ; 73(6): 2311-2325, 2021 06.
Article em En | MEDLINE | ID: mdl-33073396
BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. APPROACH AND RESULTS: Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I-III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan-Meier and Cox regression) was performed in an ENS-CCA training cohort (TC) and findings internally (ENS-CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS-CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS-CCA and SEER registries were reclassified into group C, respectively. In the ENS-CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18-5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS-CCA iVC (HR, 2.93; 95% CI, 2.04-4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68-2.09; P < 0.001). CONCLUSIONS: iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including "liver metastases: multiple liver lesions, with or without vascular invasion" as an "M1a stage," is suggested.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Neoplasias Hepáticas / Estadiamento de Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Neoplasias Hepáticas / Estadiamento de Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article